Trial Profile
Prospective, Multi-Center, Observational, Program to Assess Retention Rate, Persistence and Adherence in Population of Spondylarthritis (Ankylosing Spondylitis and Psoriatic Arthritis) Patients Treated With Adalimumab in Routine Clinical Settings in Russian Federation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Oct 2019
Price :
$35
*
At a glance
- Drugs Adalimumab (Primary)
- Indications Ankylosing spondylitis; Psoriatic arthritis; Spondylarthritis
- Focus Therapeutic Use
- Sponsors AbbVie
- 22 Oct 2019 Status changed from active, no longer recruiting to completed.
- 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
- 11 Jan 2017 Status changed from not yet recruiting to recruiting.